SCHEMBL14096590

SCHEMBL14096590

Cc1ccc(Cl)c(C(=O)NC(=S)Nc2cccc([N+](=O)[O-])c2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.62
▸ MAPT P10636 8/20 0.61
▸ RAB9A P51151 2/20 0.61
▸ NPC1 O15118 2/20 0.61
▸ KMT2A Q03164 8/20 0.57
▸ SMN1; SMN2 Q16637 7/20 0.57
▸ ALDH1A1 P00352 6/20 0.57
▸ GAA P10253 4/20 0.57
▸ LMNA P02545 2/20 0.57
▸ HTT P42858 3/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ MEN1 O00255 6/20 0.55
▸ ALOX12 P18054 1/20 0.53
▸ RORC P51449 2/20 0.53
▸ TP53 P04637 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ PKM P14618 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14096478 0.86 MAPT (0.70) POLBMAPTRAB9ANPC1KMT2A
SCHEMBL14808169 0.83 MAPT (0.80) POLBMAPTRAB9ANPC1KMT2A
SCHEMBL15778626 0.81 POLB (0.66) POLBMAPTRAB9ANPC1KMT2A
SCHEMBL15778485 0.81 MAPT (0.76) POLBMAPTRAB9ANPC1KMT2A
SCHEMBL7127748 0.79 SMN1; SMN2 (0.74) MAPTRAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL7130551 0.79 RORC (0.82) POLBMAPTRAB9AKMT2ASMN1; SMN2
SCHEMBL16431545 0.77 P2RX1 (0.79) POLBMAPTRAB9AKMT2ASMN1; SMN2
SCHEMBL17897747 0.76 MAPT (0.68) POLBMAPTRAB9ANPC1KMT2A
SCHEMBL14363303 0.76 P2RX1 (0.73) POLBMAPTRAB9ANPC1KMT2A
SCHEMBL30434704 0.75 KMT2A (0.82) POLBMAPTRAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv RNASE1, SARS1, EIF2AK2 POLB 70/4885MAPT 4038/4885RAB9A 3144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback